Advertisement

Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis

Javier I. Muñoz-González, Iván Álvarez-Twose, María Jara-Acevedo, Ana Henriques, Esther Viñas, Carlos Prieto, Laura Sánchez-Muñoz, Carolina Caldas, Andrea Mayado, Almudena Matito, Noelia Dasilva-Freire, Alberto Orfao and Andrés C. García-Montero

Article Information

Citation 
vol. 134 no. 5 456-468
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted November 19, 2018
  • Accepted May 23, 2019
  • Published online August 1, 2019.

Article Versions


Contributors 
  • Javier I. Muñoz-González, 1Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service, NUCLEUS, Universidad de Salamanca, Salamanca, Spain; 2Spanish Network on Mastocytosis, Toledo and Salamanca, Spain; 3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; 4Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain;
  • Iván Álvarez-Twose, 2Spanish Network on Mastocytosis, Toledo and Salamanca, Spain; 3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; 5Instituto de Estudios de Mastocitosis de Castilla La Mancha, Virgen del Valle Hospital, Toledo, Spain; and
  • María Jara-Acevedo, 2Spanish Network on Mastocytosis, Toledo and Salamanca, Spain; 3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; 4Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain; 6Sequencing Service and
  • Ana Henriques, 2Spanish Network on Mastocytosis, Toledo and Salamanca, Spain; 3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; 5Instituto de Estudios de Mastocitosis de Castilla La Mancha, Virgen del Valle Hospital, Toledo, Spain; and
  • Esther Viñas, 2Spanish Network on Mastocytosis, Toledo and Salamanca, Spain; 6Sequencing Service and
  • Carlos Prieto, 7Bioinformatics Service, NUCLEUS, Universidad de Salamanca, Salamanca, Spain
  • Laura Sánchez-Muñoz, 2Spanish Network on Mastocytosis, Toledo and Salamanca, Spain; 3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; 5Instituto de Estudios de Mastocitosis de Castilla La Mancha, Virgen del Valle Hospital, Toledo, Spain; and
  • Carolina Caldas, 1Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service, NUCLEUS, Universidad de Salamanca, Salamanca, Spain; 2Spanish Network on Mastocytosis, Toledo and Salamanca, Spain; 3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; 4Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain;
  • Andrea Mayado, 1Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service, NUCLEUS, Universidad de Salamanca, Salamanca, Spain; 2Spanish Network on Mastocytosis, Toledo and Salamanca, Spain; 3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; 4Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain;
  • Almudena Matito, 2Spanish Network on Mastocytosis, Toledo and Salamanca, Spain; 3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; 5Instituto de Estudios de Mastocitosis de Castilla La Mancha, Virgen del Valle Hospital, Toledo, Spain; and
  • Noelia Dasilva-Freire, 1Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service, NUCLEUS, Universidad de Salamanca, Salamanca, Spain; 2Spanish Network on Mastocytosis, Toledo and Salamanca, Spain; 3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; 4Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain;
  • Alberto Orfao, 1Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service, NUCLEUS, Universidad de Salamanca, Salamanca, Spain; 2Spanish Network on Mastocytosis, Toledo and Salamanca, Spain; 3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; 4Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain;
  • Andrés C. García-Montero, 1Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service, NUCLEUS, Universidad de Salamanca, Salamanca, Spain; 2Spanish Network on Mastocytosis, Toledo and Salamanca, Spain; 3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; 4Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output